IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Advanced Malignant Tumors Lymphomas
Conditions
Advanced Malignant Tumors Lymphomas
Trial Timeline
Jan 14, 2021 → Feb 28, 2023
NCT ID
NCT04338659About IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection
IBI322 Recombinant anti-human CD47/PD-L1 bispecific antibody injection is a phase 1 stage product being developed by Innovent Biologics for Advanced Malignant Tumors Lymphomas. The current trial status is completed. This product is registered under clinical trial identifier NCT04338659. Target conditions include Advanced Malignant Tumors Lymphomas.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04338659 | Phase 1 | Completed |
Competing Products
20 competing products in Advanced Malignant Tumors Lymphomas